Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Strata Critical Medical (SRTAW) Cash & Equivalents (2019 - 2025)

Historic Cash & Equivalents for Strata Critical Medical (SRTAW) over the last 7 years, with Q3 2025 value amounting to $22.8 million.

  • Strata Critical Medical's Cash & Equivalents rose 1360.6% to $22.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.8 million, marking a year-over-year increase of 1360.6%. This contributed to the annual value of $16.1 million for FY2024, which is 4233.85% down from last year.
  • Latest data reveals that Strata Critical Medical reported Cash & Equivalents of $22.8 million as of Q3 2025, which was up 1360.6% from $58.8 million recorded in Q2 2025.
  • Over the past 5 years, Strata Critical Medical's Cash & Equivalents peaked at $186.6 million during Q2 2022, and registered a low of $2.5 million during Q1 2022.
  • Its 5-year average for Cash & Equivalents is $36.2 million, with a median of $30.0 million in 2021.
  • The largest annual percentage gain for Strata Critical Medical's Cash & Equivalents in the last 5 years was 157223.56% (2023), contrasted with its biggest fall of 7998.03% (2023).
  • Quarter analysis of 5 years shows Strata Critical Medical's Cash & Equivalents stood at $2.6 million in 2021, then surged by 1492.99% to $41.3 million in 2022, then crashed by 32.57% to $27.9 million in 2023, then crashed by 42.34% to $16.1 million in 2024, then surged by 41.57% to $22.8 million in 2025.
  • Its Cash & Equivalents was $22.8 million in Q3 2025, compared to $58.8 million in Q2 2025 and $34.8 million in Q1 2025.